The Evolving Standard of Care in Metastatic Triple-Negative Breast Cancer
By Karine Tawagi, MD - Last Updated: December 19, 2024Drs. Karine Tawagi and Adam Brufsky continue their discussion with an overview on the best treatments in metastatic triple-negative breast cancer (TNBC) space. Dr. Brufsky especially recommends one such therapy, Trodelvy (sacituzumab govitecan) in this patient population.
Advertisement
Advertisement
Related Posts
Drs. Karine Tawagi and Adam Brufsky discuss the challenges of navigating treatment in patients with mTNBC.
A study sought to assess if a treatment combination inhibits tumor growth and metastasis in TNBC.
Sacituzumab govitecan-related neutropenia can be effectively treated using G-CSF prophylaxis in patients with mTNBC.
630 Madison Ave.
Manalapan, NJ 07726
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.